Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …

Abstract The Clinical Practice Manual for Hepatocellular Carcinoma was published based
on evidence confirmed by the Evidence-based Clinical Practice Guidelines for …

This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …

The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates
and insights - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Background Transarterial chemoembolization (TACE) is the recommended treatment for
intermediate hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …

The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …

Objective This trial compared the efficacy and safety of transarterial chemoembolisation
(TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint …

Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …